Stephen Hoge - 27 May 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
27 May 2022
Net transactions value
-$887,892
Form type
4
Filing time
01 Jun 2022, 17:15:16 UTC
Previous filing
25 May 2022
Next filing
14 Jun 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $327,278 +2,410 +0.15% $135.80 1,625,230 27 May 2022 Direct F1
transaction MRNA Common Stock Options Exercise $7,357 +7,431 +0.46% $0.9900* 1,632,661 31 May 2022 Direct F2
transaction MRNA Common Stock Sale $145,255 -999 -0.06% $145.40 1,631,662 31 May 2022 Direct F3
transaction MRNA Common Stock Sale $1,077,272 -7,431 -0.46% $144.97 1,624,231 31 May 2022 Direct F2
holding MRNA Common Stock 4,116 27 May 2022 By Valhalla, LLC
holding MRNA Common Stock 151,933 27 May 2022 By Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -2,410 -12% $0.000000 16,873 27 May 2022 Common Stock 2,410 $0.000000 Direct F1, F5
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -7,431 -100% $0.000000* 0 31 May 2022 Common Stock 7,431 $0.9900 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F3 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F4 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.
F6 This option is fully vested and exercisable.